Navigation Links
GW Pharmaceuticals Commences Phase 1b/2a Clinical Trial for the Treatment of Glioblastoma Multiforme (GBM)
Date:11/11/2013

LONDON, Nov. 11, 2013 /PRNewswire/ -- GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW") a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today it has commenced a Phase 1b/2a clinical trial for the treatment of Recurrent Glioblastoma Multiforme (GBM).

Glioma describes any tumor that arises from the glial tissue of the brain. GBM is a particularly aggressive tumor that forms from abnormal growth of glial tissue. According to the New England Journal of Medicine, GBM accounts for approximately 50% of the 22,500 new cases of brain cancer diagnosed in the United States each year. Treatment options are limited and expected survival is a little over one year. GBM is considered a rare, or orphan, disease by the FDA and the European Medicines Agency, or EMA.

This study follows several years of pre-clinical research conducted by GW in the field of glioma which has demonstrated that cannabinoids inhibit the viability of glioma cells both in vitro and in vivoi,ii via apoptosis or programmed cell death, may also affect angiogenesis, and have demonstrated tumor growth-inhibiting action and an improvement in the therapeutic efficacy of temozolomide, a standard treatment for glioma. In addition, GW has shown tumor response to be positively associated with tissue levels of cannabinoids. GW has identified the putative mechanism of action for our cannabinoid product candidate, where autophagy and programmed cell death are stimulated via stimulation of the TRB3 pathway.

"We are very excited about moving this compound into further human study and the prospects of cannabinoids as new anti-cancer treatments. This is GW's first clinical study of cannabinoids as a potential treatment to inhibit tumor growth," stated Dr. Stephen Wri
'/>"/>

SOURCE GW Pharmaceuticals plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... “Our nation's healthcare system is broken, ... Furthermore, every governmental and professional entity that has ... of unorganized dysfunction shares in that enormous blame. ... as a device to use in an effort ... have accumulated through the years leading to the ...
(Date:8/21/2014)... A Finnish-Swedish research group at the Institute for ... Karolinska institutet, Stockholm, has developed a novel "man ... infection. This innovative diagnostic aid was described in ... August. The method is based on computer vision ... systems combined with visualization of only the diagnostically ...
(Date:8/21/2014)... , August 21, 2014 ... http://www.researchandmarkets.com/research/3zh3q8/global_hormone ) has announced the addition of ...  report to their offering.       ... as hormone therapy, is a means of ... produced by the body. This type of ...
(Date:8/21/2014)... New Rochelle, N.Y. (PRWEB) August 21, 2014 ... it is the first private college in the Mid-Hudson ... The College will now begin accepting applications from qualified ... , “We are very pleased to have been ... to support Governor Cuomo’s transformative initiative to stimulate economic ...
Breaking Biology Technology:5 Great Mistakes in Healthcare and How to Fix Them by Dr. Ira Williams 2A novel 'man and machine' decision support system makes malaria diagnostics more effective 2Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3
... Third Wave Technologies Inc. (Nasdaq: TWTI) today announced ... assays to RIKEN in Japan for use in various large ... Wave has been supplying its Invader SNP assays to Dr. ... Medicine at RIKEN, director of the Genome Center ...
... hit the road , ,MILWAUKEE - Ask any successful ... and you will get one answer: SALES. Despite this, sales ... in business school curricula today. What They Dont Teach You ... the Kellogg Alumni Club of Chicago titled Creating, Growing and ...
... between U.S. white collar workers and those in India is ... ,IT Manager ,U.S: $55,000 ,India: $8,500 , ,Accountant ,U.S.: $41,000 ... States were almost solely in the manufacturing sector, as more ... other Latin American countries to cut costs. Not to mention ...
Cached Biology Technology:Sales Strategies for the High-Tech Entrepreneur 2Sales Strategies for the High-Tech Entrepreneur 3Sales Strategies for the High-Tech Entrepreneur 4Sales Strategies for the High-Tech Entrepreneur 5Outsourcing Offshore - Wisconsin Companies Sending Work Abroad 2Outsourcing Offshore - Wisconsin Companies Sending Work Abroad 3
(Date:8/21/2014)... WHEN: , Saturday to Wednesday, Oct. 18-22, 2014 ... 111 W. Harbor Drive, San Diego, CA 92101 ... sessions and other presentations of the latest research ... Opening plenary session featuring high-scoring abstracts on rare ... of various cancers, and treatment for sun sensitivity ...
(Date:8/21/2014)... successfully replicated one of the crucial steps in photosynthesis, ... which could manufacture hydrogen as a fuel. , "Water ... exciting prospect to use them to create hydrogen, and ... from the ARC Centre of Excellence for Translational Photosynthesis ... offers potential as a zero-carbon replacement for petroleum products, ...
(Date:8/20/2014)... ITHACA, N.Y. In a study of 158 pregnant ... the craving and intentional consumption of ice, cornstarch, ... items, reports a new Cornell study. , Moreover, such ... teens who did not eat nonfood substances. , Pregnant ... low hemoglobin, which can lead to iron deficiency and ...
Breaking Biology News(10 mins):American Society of Human Genetics 2014 Annual Meeting 2Water and sunlight the formula for sustainable fuel 2Pica in pregnant teens linked to low iron 2
... tap the vast, unexplored reaches of the earth,s microbial ... DOE Joint Genome Institute (DOE JGI) has announced its ... undertake in the coming year. The 44 projects, culled ... Program (CSP), represent over 60 billion nucleotides of data ...
... in Spanish . Most of the functions ... proteins, which recognise their binding partner by affinity features localized ... however, the most complicated to study from the perspective of ... interaction is brief and occurs through a large section of ...
... trials to find a successful vaccine against footrot in ... funding of $663,000 from Australian Wool Innovation (AWI) ... at Monash University,s Australian Research Council Centre of Excellence ... of Sydney. Chief investigator Professor Julian Rood said ...
Cached Biology News:US Department of Energy Joint Genome Institute announces new genome sequencing projects 2US Department of Energy Joint Genome Institute announces new genome sequencing projects 3US Department of Energy Joint Genome Institute announces new genome sequencing projects 4US Department of Energy Joint Genome Institute announces new genome sequencing projects 5US Department of Energy Joint Genome Institute announces new genome sequencing projects 6US Department of Energy Joint Genome Institute announces new genome sequencing projects 7Scientists reveal the key mechanisms for affinity between transient binding proteins 2Footrot vaccine closer than ever 2
... ELx50 is a fast and versatile automated ... our patented Dual-ActionTM 16-channel manifold. This breakthrough ... dispense and aspiration manifolds for overfill washing ... 384-well formats. The problem of fitting dispense ...
... The HybArray 12™ is an automated ... microarrays. The system automates both the hybridization ... onto glass slides. A single instrument can ... time in pairs and has multi-protocol software, ...
... S&S Custom Array Service enables scientists who have ... to have FAST Slides printed with proteins from ... Processing of the arrays is performed by the ... S&S to discuss your needs with an expert ...
Acetylcholinesterase (human brain, AChE)...
Biology Products: